NASDAQ:ASND
Ascendis Pharma A/S Stock News
$137.20
-3.90 (-2.76%)
At Close: May 03, 2024
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
Ascendis Pharma: A Promising Platform And A Rich Valuation
09:38am, Friday, 10'th Sep 2021
The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
12:30pm, Wednesday, 08'th Sep 2021
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Ascendis Pharma A/S Announces Upcoming Investor Presentations
05:09pm, Tuesday, 07'th Sep 2021
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
04:59pm, Tuesday, 07'th Sep 2021
– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged acti
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
07:43pm, Wednesday, 01'st Sep 2021
COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
04:01pm, Tuesday, 31'st Aug 2021
COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new t
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
02:00pm, Tuesday, 31'st Aug 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals
Why Shares of Ascendis Soared This Week
09:46pm, Thursday, 26'th Aug 2021
The pharmaceutical company saw its shares jump more than $26.
Here's Why Ascendis Pharma Shares Are Surging Higher Today
02:13pm, Thursday, 26'th Aug 2021
Approval of the company's weekly growth hormone is making investors smile today.
See Why Ascendis Pharma Stock Is Shining On Thursday
11:34am, Thursday, 26'th Aug 2021
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in k
ASND Stock: Over 20% Increase Pre-Market Explanation
07:46am, Thursday, 26'th Aug 2021
The stock price of Ascendis Pharma A/S (Nasdaq: ASND) increased by over 20% pre-market. This is why it happened.
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2021 Results - Earnings Call Transcript
01:37am, Thursday, 26'th Aug 2021
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2021 Results - Earnings Call Transcript
These 2 Stocks Soared Double Digits After Hours
06:20pm, Wednesday, 25'th Aug 2021
Find out where the big winners were late Wednesday.
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results
04:12pm, Wednesday, 25'th Aug 2021
– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –
